AstraZeneca’s Imfinzi Fails Again In Head And Neck Cancer
KESTREL Follows EAGLE To Crash Land
The Phase III KESTREL study evaluating Imfinzi missed its primary overall survival benefit and a key secondary outcome in first-line recurrent or metastatic head and neck squamous cell carcinoma.
